Kymera Therapeutics: KT-579 Data Overshadows a Weak Q3

Kymera's Q3 2026 GAAP net loss of $1.32 per share came in missing expectations, with revenue at zero. The shortfall traces to management's decision not to recognize further collaboration revenue in 2026, leaving the quarter without the Gilead payments booked a year ago.

KT-579, the company's IRF5 degrader, reached at least 90% median IRF5 degradation across multiple dose levels in its Phase 1 healthy volunteer trial, with safety comparable to placebo and no serious or severe adverse events. CEO Nello Mainolfi said the findings exceed expectations in depth of degradation, safety, and suppression of downstream cytokines and gene transcripts. Investors are pricing the clinical read, not the quarter.

R&D expenses expanded to $128.5 million, widening the net loss year over year. That spending reflects investment in the STAT6 program, platform expansion, and a larger research organization, building toward multiple Phase 2b and Phase 3 studies.

Year-end topline data from the KT-621 BROADEN2 Phase 2b atopic dermatitis trial is the next event that moves the stock, and the last patient completed their week 16 visit in October 2026. With $1.65 billion in cash funding operations into 2029, Kymera has the runway to absorb rising losses while that data arrives.

Beyond atopic dermatitis, the KT-579 LUMORA Phase 1b lupus trial is planned to start by early 2027, and topline data from the KT-621 BREADTH asthma trial are expected in late 2027. The next twelve months carry several binary events that make the cash position and clean KT-579 safety data directly relevant to the risk investors hold now.